EXIT071 is a Dutch deep-tech company, spin-off from Leiden University, based at the Leiden Bio Science Park. The company is dedicated to developing advanced exosome isolation technologies for biomarker discovery, diagnostics, and therapeutic applications. By leveraging its proprietary innovations, EXIT071 aims to accelerate the integration of exosome-based solutions into precision medicine.
EXIT071 has developed a platform technology, the EXIT (EXosome Isolation Tool), for scalable exosome isolation and biomarker analysis. Exosomes are nanosized extracellular vesicles present in body fluids, carrying molecular signatures of their originating cells, making them highly valuable for diagnostics and understanding disease mechanisms. EXIT071’s platform is based on its patented depletion zone isotachophoresis technology, invented at Leiden University, enabling simultaneous separation and enrichment of exosomes in a microfluidic chip. This technology seamlessly integrates with molecular analysis methods such as mass spectrometry, sequencing, PCR, enabling automated workflows for high-throughput biomarker analysis.
EXIT071 platform aims to enhance the efficiency and scalability of exosome isolation, a critical step in unlocking the potential of extracellular vesicles as biomarkers for disease detection and treatment monitoring. By improving current isolation technologies, EXIT071 seeks to provide researchers, companies and clinicians with more reliable and high-yield solutions, ultimately facilitating breakthroughs in precision medicine.
